Drugs / PCV20
PCV20
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07406347 | Jan 2027 → Oct 2028 expected | bacterial pneumonia | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07712575 | Aug 2026 → Jun 2028 expected | — | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07406334 | May 2026 → Feb 2027 expected | bacterial pneumonia | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07428759 | Mar → Dec 2026 expected | bacterial pneumonia | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07105722 | Aug 2025 → May 2026 | bacterial pneumonia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05417165 | Sep 2023 → Oct 2026 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Seema Bhat | Recruiting | No outcome recorded |
| Phase 2 | NCT05412030 | Jun 2022 → Sep 2025 | streptococcal pneumonia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT05183854 | Jan 2022 → Mar 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | University of Utah | Recruiting | No outcome recorded |
| Phase 2 | NCT03512288 | Apr 2018 → Feb 2020 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT03313037 | Oct 2017 → Dec 2018 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06824181 | Feb 2025 → Sep 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05879107 | May → Dec 2023 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT07135453 | Jul 2026 → Mar 2027 expected | pneumococcal infection | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 4 | NCT07252791 | Jan → Dec 2026 expected | autoimmune disease | University of Sao Paulo General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06049134 | Oct 2023 → Dec 2026 expected | lymphoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05767606 | Mar → Jul 2023 | COVID-19, pneumococcal infection | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT05170399 | Sep 2022 → Aug 2026 overdue | lymphoma | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 27 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07300267 Comparator | Jan 2026 → Oct 2028 expected | pneumococcal infection | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT07168915 Comparator | Oct 2025 → Jul 2027 expected | — | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06986239 Comparator | Jul 2025 → Apr 2026 overdue | — | LiteVax BV | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06611033 Comparator | Sep 2024 → Jan 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT05540028 Comparator | Sep 2022 → Jul 2023 | — | Inventprise Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06182124 Comparator | Dec 2023 → May 2026 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 1/2 | NCT06151288 Comparator | Nov 2023 → Jul 2024 | — | Vaxcyte, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT05266456 Comparator | Feb 2022 → Jan 2023 | — | Vaxcyte, Inc. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06790290 Comparator | Jan → Apr 2025 overdue | pneumococcal infection | Inventprise Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06720038 Comparator | Nov 2024 → Dec 2027 expected | — | Vaxcyte, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06077656 Comparator | Oct 2023 → May 2024 | — | Inventprise Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05844423 Comparator | Mar 2023 → Aug 2025 | — | Vaxcyte, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05297578 Comparator | Jun 2022 → Feb 2023 | — | Vaxcyte, Inc. | Completed | No outcome recorded |
| Phase 314 trials | ||||||
| Phase 3 | NCT07660198 Comparator | Jun 2026 → Dec 2027 expected | pneumococcal infection | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT07573462 Comparator | May 2026 → Dec 2028 expected | pneumococcal infection | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT07425392 Comparator | Feb 2026 → Mar 2027 expected | — | Vaxcyte, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07284654 Comparator | Dec 2025 → Jan 2027 expected | — | Vaxcyte, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07160244 Background | Aug 2025 → Nov 2028 expected | — | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT06806137 Background | May 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06855160 Background | Apr 2025 → Sep 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06824194 Comparator | Feb 2025 → Oct 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06740630 Background | Jan 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06736041 Comparator | Dec 2024 → May 2027 expected | — | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06693895 Background | Nov 2024 → Nov 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06397768 Background | May 2024 → Sep 2025 | respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded |
| Phase 3 | NCT05425732 Comparator | Jul 2022 → May 2023 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03621670 Background | Jul 2018 → Dec 2024 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-10-23 | Pfizer | Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older pfizer.com ↗ |
| 2024-03-13 | Pfizer | European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease pfizer.com ↗ |
| 2023-04-27 | Pfizer | U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children pfizer.com ↗ |
| 2022-01-12 | Pfizer | Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released pfizer.com ↗ |
| 2021-10-20 | Pfizer | Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults pfizer.com ↗ |
| 2021-09-29 | Pfizer | Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released pfizer.com ↗ |
| 2021-06-08 | Pfizer | U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older pfizer.com ↗ |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 46 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCV20 | “Participants were block randomised (1:1:1:1) using a web-based randomisation and trial management system to receive a dose of intramuscular low-dose, mid-dose, or high-dose...” PMID 41864214 ↗ Mar 202626“The aim of this clinical trial was to assess the safety, tolerability, and immunogenicity of three different doses of VAX-24 compared to pneumococcal 20-valent conjugate...” PMID 38061367 ↗ Dec 2023 “A 20-valent PCV (PCV20) has been developed to add coverage for 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) to those in the existing 13-valent PCV (PCV13).” PMID 34525007 ↗ Oct 2021 “A 20-valent PCV (PCV20) containing capsular polysaccharide conjugates of serotypes present in the 13-valent PCV (PCV13) and 7 new serotypes” PMID 32716500 ↗ Oct 2021 “PCV20 (Prevenar 20) vaccine administered intramuscularly in 1 dose depending on age and prior vaccination history.” NCT07252791 ↗ “PCV20 (Prevnar 20) was the control.” PMID 41576705 ↗ Jan 2026 “Will receive PCV20” NCT07135453 ↗ |
| Known as | 20-valent PCV | “A 20-valent PCV (PCV20) has been developed to add coverage for 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) to those in the existing 13-valent PCV (PCV13).” PMID 34525007 ↗ Oct 20211“A 20-valent PCV (PCV20) containing capsular polysaccharide conjugates of serotypes present in the 13-valent PCV (PCV13) and 7 new serotypes” PMID 32716500 ↗ Oct 2021 |
| Known as | 20-valent pneumococcal conjugate vaccine (20vPnC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07660198 ↗ |
| Known as | Apexxnar | “PCV20 (Apexxnar®) plus placebo” NCT05767606 ↗ |
| Known as | PCV13 | “Prevnar 20 (PCV13) was administered intramuscularly as a booster dose on Day 301 group who have received 3 PCV13 doses before 12 months of age but have not received their...” NCT03621670 ↗ |
| Known as | pneumococcal 20-valent conjugate vaccine | “The aim of this clinical trial was to assess the safety, tolerability, and immunogenicity of three different doses of VAX-24 compared to pneumococcal 20-valent conjugate...” PMID 38061367 ↗ Dec 2023 |
| Known as | Prevenar 20 | “PCV20 (Prevenar 20) vaccine administered intramuscularly in 1 dose depending on age and prior vaccination history.” NCT07252791 ↗ |
| Known as | Prevnar 20 | “Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1” NCT07425392 ↗12“0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1” NCT05297578 ↗ “PCV20 (Prevnar 20) was the control.” PMID 41576705 ↗ Jan 2026 |
| Known as | Prevnar 20 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06824181 ↗ |
| Known as | Prevnar 20, PCV20 | “Prevnar 20, PCV20” NCT05297578 ↗ |
| Known as | Streptococcus pneumoniae vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06397768 ↗ |
| Modality | Vaccine | “A 20-valent PCV (PCV20)” PMID 32716500 ↗ Oct 2021 |
| Route | Intramuscular | “a single intramuscular dose of multivalent pneumococcal conjugate vaccine” NCT03313037 ↗ |